Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Identification of a Subtype of Poorly Differentiated Invasive Ductal Carcinoma of the Breast Based on Vimentin and E-cadherin Expression

Texto completo
Autor(es):
Orlandin, Leonardo Fleury [1] ; Candid dos Reis, Francisco Jose [1] ; da Silveira, Willian Abraham [1] ; Tiezzi, Marcelo Guimaraes [1] ; de Andrade, Jurandyr Moreira [1] ; Ribeiro-Silva, Lfredo [1] ; Deaton, Ryan [1] ; Bosland, Maarten [2] ; Tiezzi, Aniel Guimaraes [1]
Número total de Autores: 9
Afiliação do(s) autor(es):
[1] Univ Sao Paulo, Hosp Clin, Sch Med, Breast Dis Div, Dept Gynecol & Obstet, Av Bandeirantes 3900, BR-14040900 Ribeirao Preto, SP - Brazil
[2] Univ Illinois, Chicago, IL - USA
Número total de Afiliações: 2
Tipo de documento: Artigo Científico
Fonte: Revista Brasileira de Ginecologia e Obstetrícia; v. 40, n. 12, p. 779-786, DEC 2018.
Citações Web of Science: 3
Resumo

Objective The use of molecular markers can identify a subgroup of tumors with distinct recurrence patterns. The present study aimed to characterize the immunohistochemical expression of vimentin (VIM), of E-cadherin (CDH1), and of cytokeratin 5 (CK5) in patients with invasive ductal carcinomas (IDCs). Methods We have constructed a tissue microarray (TMA) from 87 patients with IDC of the breast. Immunohistochemistry (IHC) was performed to study the expression of estrogen and progesterone receptors (ER and PgR), human epidermal growth factor receptor 2 (HER2), VIM, CDH1, CK5, and Ki67. The tumors were classified as lumina) A and B (n = 39), HER2 enriched (n = 25), and triple-negative (TNBC) (n = 23), based on the IHC expression. Results We have observed that luminal A and B tumors lack the VIM+/CDH1(-/low) phenotype. This phenotype was observed in 16.5% of the HER2+ tumors and in 60% of the TNBC tumors (p = 0.0001). Out of a total of 20 TNBC tumors, the CK5 (basal-like marker) was positive in 11 of them. The VIM+/CDH1(-/low) phenotype was observed in 5 CK5- TNBC tumors (45%) and in 7 out of 9 CK5+ TNBC tumors (78%) (p = 0.02). The median Ki67 index in the VIM+/CDH1(-/low) tumors was 13.6 (range: 17.8-45.4) compared with 9.8 (range: 4.1-38.1) in other tumors (p = 0.0007). The presence of lymph node metastasis was less frequent in patients with VIM+/CDH1(-/low) tumors (23% versus 61%; chi(2) test; p = 0.01). Conclusion Our findings suggest that the expression of VIM and CDH1 can identify a subset of IDCs of the breast with a mesenchymal phenotype associated with poor prognosis, high-grade lesion, and high mitotic index. (AU)

Processo FAPESP: 08/09294-9 - Transição epitélio-mesenquimal na carcinogênese mamária
Beneficiário:Daniel Guimarães Tiezzi
Modalidade de apoio: Auxílio à Pesquisa - Regular